ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

Impact · against what's priced in

ANI Pharmaceuticals' offer to acquire Egetis Therapeutics is a material expansion of its rare disease business. Egetis is expected to see an immediate price re-rating to the offer premium, while ANI may see a modest positive reaction based on the scale of the acquisition.

EGETI+0.50

No priced-in read yet